$KRTL KRTL Holding Group Highlights Bolivian Innov
Post# of 26483
(Total Views: 125)
Posted On: 11/04/2025 10:39:20 AM
$KRTL KRTL Holding Group Highlights Bolivian Innovation CaviGuard, Manufactured by SIGMA, as Global Model in Non-Invasive Dental Care
https://www.otcmarkets.com/stock/KRTL/news/KR...?id=498549
KRTL Holding Group Inc. (OTC: KRTL) ("KRTL" or the "Company"
is proud to spotlight CaviGuard, an innovative dental care system developed in Bolivia and manufactured by its majority-owned subsidiary, Industria Químico-Farmacéutica SIGMA Corp. The system utilizes a non-invasive protocol that avoids drilling and anesthesia, offering a practical alternative to conventional cavity treatment. Now expanding beyond Bolivia, CaviGuard is being introduced in Brazil and the United States as part of broader efforts to improve access to preventive and therapeutic dental care.
CaviGuard is designed to address the global burden of untreated dental caries, particularly in underserved and rural communities. The system eliminates the need for drills or anesthesia, allowing for safe, comfortable, and rapid treatment using a protocol based on silver diamine fluoride (SDF) and fluoride varnish (FV). Developed over more than a decade, CaviGuard has been deployed in thousands of patients and validated through field trials and academic research.
"CaviGuard exemplifies the kind of scalable, community-centered innovation that aligns perfectly with KRTL's international strategy," said Cesar Herrera, CEO of KRTL Holding Group Inc. “Its expansion into new markets is a reflection of both its clinical value and its manufacturing quality through SIGMA.”
Unlike conventional dental procedures that require drills, anesthesia, and clinical infrastructure, CaviGuard represents a novel medical device solution tailored for portability, cost-effectiveness, and patient comfort. By eliminating invasive steps, it lowers barriers to care—particularly in resource-limited settings. According to the World Health Organization, untreated dental caries is the most common health condition globally, contributing to the 3.5 billion people affected by oral diseases. The global dental consumables market—which includes products like fluoride varnishes and non-invasive cavity treatments—was valued at approximately USD 36 billion in 2024, according to Grand View Research. As the licensed manufacturer, SIGMA ensures each CaviGuard unit is produced in accordance with international GMP standards, supporting quality, consistency, and alignment with global public health objectives.
The CaviGuard system leverages a unit-dose protocol for hygienic, controlled application and includes a Proprietary housing and delivery system to optimize comfort and efficiency. Designed for ease of use in low-infrastructure settings, the treatment is already in use in:
Community and rural clinics across Bolivia
Public health programs in partnership with UNIVALLE and the Bolivian Food Bank
Clinics in Brazil aligned with national prevention strategies
Select providers in the United States focused on low-income and pediatric populations
“Our mission has always been to reduce barriers to essential oral health services,” said Patricia Wilstermann, CEO of SIGMA. “By producing CaviGuard at scale, we’re enabling frontline health professionals to treat cavities without fear, pain, or costly infrastructure.”
CaviGuard has also launched training and certification programs for dental professionals and public health providers. This includes partnerships with universities and nonprofit groups to ensure appropriate deployment and adherence to international standards.
Why It Matters
Dental cavities remain the most common chronic disease globally, affecting billions of people, particularly in low-resource environments where access to safe, affordable treatment is limited. CaviGuard directly addresses this global health challenge with a system that eliminates the need for drills, anesthesia, or electricity. Clinical outcomes have shown cavity arrest rates of up to 96%, offering a non-invasive and highly effective alternative to traditional dental care. By reducing treatment anxiety—especially in children—and enabling mass deployment in schools, mobile units, and community clinics, the solution meets both public health and practical demands. With its cross-border adoption already underway, CaviGuard exemplifies how innovation born in South America can transform global standards in oral health delivery.
https://www.otcmarkets.com/stock/KRTL/news/KR...?id=498549
KRTL Holding Group Inc. (OTC: KRTL) ("KRTL" or the "Company"
is proud to spotlight CaviGuard, an innovative dental care system developed in Bolivia and manufactured by its majority-owned subsidiary, Industria Químico-Farmacéutica SIGMA Corp. The system utilizes a non-invasive protocol that avoids drilling and anesthesia, offering a practical alternative to conventional cavity treatment. Now expanding beyond Bolivia, CaviGuard is being introduced in Brazil and the United States as part of broader efforts to improve access to preventive and therapeutic dental care. CaviGuard is designed to address the global burden of untreated dental caries, particularly in underserved and rural communities. The system eliminates the need for drills or anesthesia, allowing for safe, comfortable, and rapid treatment using a protocol based on silver diamine fluoride (SDF) and fluoride varnish (FV). Developed over more than a decade, CaviGuard has been deployed in thousands of patients and validated through field trials and academic research.
"CaviGuard exemplifies the kind of scalable, community-centered innovation that aligns perfectly with KRTL's international strategy," said Cesar Herrera, CEO of KRTL Holding Group Inc. “Its expansion into new markets is a reflection of both its clinical value and its manufacturing quality through SIGMA.”
Unlike conventional dental procedures that require drills, anesthesia, and clinical infrastructure, CaviGuard represents a novel medical device solution tailored for portability, cost-effectiveness, and patient comfort. By eliminating invasive steps, it lowers barriers to care—particularly in resource-limited settings. According to the World Health Organization, untreated dental caries is the most common health condition globally, contributing to the 3.5 billion people affected by oral diseases. The global dental consumables market—which includes products like fluoride varnishes and non-invasive cavity treatments—was valued at approximately USD 36 billion in 2024, according to Grand View Research. As the licensed manufacturer, SIGMA ensures each CaviGuard unit is produced in accordance with international GMP standards, supporting quality, consistency, and alignment with global public health objectives.
The CaviGuard system leverages a unit-dose protocol for hygienic, controlled application and includes a Proprietary housing and delivery system to optimize comfort and efficiency. Designed for ease of use in low-infrastructure settings, the treatment is already in use in:
Community and rural clinics across Bolivia
Public health programs in partnership with UNIVALLE and the Bolivian Food Bank
Clinics in Brazil aligned with national prevention strategies
Select providers in the United States focused on low-income and pediatric populations
“Our mission has always been to reduce barriers to essential oral health services,” said Patricia Wilstermann, CEO of SIGMA. “By producing CaviGuard at scale, we’re enabling frontline health professionals to treat cavities without fear, pain, or costly infrastructure.”
CaviGuard has also launched training and certification programs for dental professionals and public health providers. This includes partnerships with universities and nonprofit groups to ensure appropriate deployment and adherence to international standards.
Why It Matters
Dental cavities remain the most common chronic disease globally, affecting billions of people, particularly in low-resource environments where access to safe, affordable treatment is limited. CaviGuard directly addresses this global health challenge with a system that eliminates the need for drills, anesthesia, or electricity. Clinical outcomes have shown cavity arrest rates of up to 96%, offering a non-invasive and highly effective alternative to traditional dental care. By reducing treatment anxiety—especially in children—and enabling mass deployment in schools, mobile units, and community clinics, the solution meets both public health and practical demands. With its cross-border adoption already underway, CaviGuard exemplifies how innovation born in South America can transform global standards in oral health delivery.
(0)
(0)